Cronos Group (NASDAQ:CRON) tops the list with a return of 107% so far in 2019. The cannabis company built up considerable momentum coming into the year when it announced that cigarette giant Altria Group (NYSE:MO) would take a 45% stake in the company for $1.8 billion. Altria ended up paying about $12.25 per share for that stake in Cronos, retaining the right to take majority control within the next several years by purchasing an extra 10% at around $14.25 per share.Since then, the stock has soared above the $20 per share mark on hopes that Altria's partnership will lead to brand-new opportunities for Cronos. Yet skeptics point out that Cronos can't match its larger rivals in terms of current production capacity or sales. If Cronos' growth can't justify its current valuation, then the stock's gains could start to evaporate.
[URL=https://www.hscapitalbank.com]Find Out More Here[/URL]